Kymera Therapeutics opened at $122.58, in line with its previous close of $122.60. In the last trading session, the stock traded between $117.31 and $124.37. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Kymera Therapeutics is now worth
$ 206.09
giving a profit of
$ 106.09 (106.09%)
Note: Past profits do not guarantee future returns.
Rating from 15 Analysts
Today's Change
$-1.26 (-1.02%)
Day High
$124.37
Day Low
$117.31
Day Open
$122.58
Prev Close
$122.60
Volume
4,30,381
1W Return
9.35%
1M Return
9.78%
3M Return
15.42%
6M Return
48.87%
1Y Return
102.14%
Market Cap ($ Mn)
10,090
PE Ratio
-
PB Ratio
6.48
PEG Ratio
-
ROE
-30.41%
ROCE
-31.75%
EPS (TTM)
$-1.55
1 Week
9.35%
1 Month
9.78%
3 Months
15.42%
6 Months
48.87%
9 Months
64.18%
Stifel maintains Buy on Kymera Therapeutics, lifts price target to $152
Stifel maintains a Buy rating on Kymera Therapeutics. Price target raised from $132 to $152. Analyst Alex Thompson issued the revised rating.
1mo agoKymera Therapeutics to present at five September investor conferences
Kymera Therapeutics to present at five investor conferences in September 2026. Events include Wells Fargo, Citi, H.C. Wainwright, Morgan Stanley, and Stifel forums. Live webcasts available via company website with archived replays.
1mo agoKymera Therapeutics to Report Q2 2026 Results on Aug 5
Kymera Therapeutics, Inc. will report second quarter 2026 financial results on August 5, 2026, hosting a concurrent video conference call and webcast at 8:30 a.m. ET. The clinical-stage biopharmaceutical company, known for its targeted protein degradation medicines, will use the event to discuss its latest performance. Investors can access the broadcast via registration or the company's website.
3mo agoKymera Therapeutics appoints Terence Rooney as Chief Medical Officer
Kymera Therapeutics appoints Terence Rooney, MD, as Chief Medical Officer on July 27, 2026. He succeeds Jared Gollob, MD, who retires after eight years but remains an advisor through year-end. Dr. Rooney joins from Johnson & Johnson, bringing experience in advancing immunology therapies.
3mo agoKuehn Law probes Kymera Therapeutics for alleged self-dealing
Kuehn Law, PLLC is investigating Kymera Therapeutics, Inc. for alleged fiduciary duty breaches involving self-dealing by officers and directors. Long-term shareholders are urged to contact the firm immediately to explore potential claims for damages and governance reforms, as there may be limited time to enforce rights. The investigation offers free consultations with no upfront costs to investors.
3mo agoKuehn Law investigates Kymera Therapeutics for fiduciary breaches
Kuehn Law, PLLC is investigating Kymera Therapeutics, Inc. for potential breaches of fiduciary duties and self-dealing by officers and directors, potentially entitling shareholders to damages. This adds to a similar investigation by Purcell & Lefkowitz LLP regarding recent corporate actions. Shareholders are encouraged to contact the law firms for free consultations to discuss their rights and options.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Kymera Therapeutics is now worth
$ 206.09
giving a profit of
$ 106.09 (106.09%)
Note: Past profits do not guarantee future returns.
